Physician profile
Rosemarie Read
NPI 1205981701
$1,490.67
in general payments reported to CMS, 2019-2025
25 companies · $236 in 2025
The $236 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $82.68 · 2021: $210 · 2022: $162 · 2023: $347 · 2024: $293 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $183.21 | 2019-2024 | Auvi-Q |
| Aytu Biopharma, INC. | $166.39 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $163.77 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi-Aventis U.S. LLC | $96.68 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.90 | 2020-2021 | |
| Cranial Technologies, INC | $81.04 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $80.64 | 2022-2025 | |
| Seqirus USA INC | $71.86 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sobi, INC | $66.78 | 2020-2023 | |
| Meridian Bioscience INC. | $60.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $57.78 | 2021 | |
| Pfizer INC. | $54.84 | 2019-2023 | |
| Hologic Sales and Service, LLC | $49.22 | 2023-2025 | Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $38.38 | 2024-2025 | Bexsero, Penmenvy, Rotarix |
| Inspire Medical Systems, INC. | $33.21 | 2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $30.69 | 2023-2024 | Ragwitek, Grastek, Odactra |
| Astrazeneca Pharmaceuticals LP | $27.35 | 2023 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $23.94 | 2024 | Ycanth |
| Ultragenyx Pharmaceutical INC. | $21.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2019 | |
| Corium, LLC | $16.22 | 2023 | Azstarys |
| Phadia US INC. | $16.02 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.92 | 2019 | |
| Neos Therapeutics, LP | $13.48 | 2023 | Adzenys Xr-Odt |
| Novo Nordisk INC | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemarie Read listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.